Atropos Health Strengthens Precision Oncology Platform with Advanced AI for Rare Disease Monitoring and Integration of ASCO Clinical Guidelines
Atropos Health, a leader in transforming real-world clinical data into personalized real-world evidence (RWE), has announced a major expansion of its oncology precision medicine capabilities through the publication of new artificial intelligence (AI) algorithms for rare disease monitoring and the integration of the American Society of Clinical Oncology (ASCO®) clinical practice guidelines into its platform. These dual advancements mark a significant milestone in Atropos Health’s mission to democratize access to evidence-based medicine and improve personalized patient care at scale.
The company also revealed that its latest research and AI technologies will be showcased at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, one of the world’s most influential gatherings in hematology, taking place in Orlando, Florida. The conference presentation underscores the growing role of real-world data and machine learning in driving earlier diagnosis, improving disease monitoring, and enhancing long-term outcomes for patients with complex and rare blood disorders.
Advancing Care for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Central to Atropos Health’s announcement is the publication of additional AI-powered tools designed to monitor disease progression in patients already diagnosed with paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening blood disorder characterized by red blood cell destruction, bone marrow failure, and a heightened risk of thrombosis. PNH can lead to a wide range of severe complications, including organ damage, chronic anemia, and life-threatening blood clots, making early detection and continuous monitoring critical to patient outcomes.
These newly introduced AI models build upon a previously published algorithm developed by Atropos Health that focused on improving the early diagnosis of PNH using large-scale, real-world clinical data. The newly released progression monitoring tools are designed to help clinicians detect subtle changes in disease activity among patients who have already been diagnosed, enabling proactive interventions before complications escalate.
The progression monitoring models leverage machine learning techniques trained on expansive real-world datasets to identify patterns that may indicate increasing disease severity or the onset of serious sequelae. By continuously evaluating patient data, these tools aim to reduce the likelihood of thrombosis, prevent organ dysfunction, and manage anemia more effectively. Importantly, these AI tools are now available for use by health systems, making advanced predictive analytics accessible beyond academic research settings and into everyday clinical practice.
By equipping care teams with earlier warnings and more precise insights, Atropos Health is helping physicians shift from reactive treatment to proactive disease management—an essential step in improving long-term outcomes for patients with rare and complex conditions such as PNH.
Presentation at the ASH Annual Meeting Demonstrates AI’s Role in Hematology Innovation
Atropos Health’s advancements in rare disease AI will be formally presented at the 67th ASH Annual Meeting and Exposition, where leading clinicians, researchers, and industry innovators gather to share the latest breakthroughs in hematology. Dr. Sandeep Jain, Director of Medical Innovation for Hematology and Oncology at Atropos Health, will present a poster titled “Early identification of patients likely to benefit from paroxysmal nocturnal hemoglobinuria workup using machine learning on large-scale real-world data.”
The presentation is scheduled as part of the poster session “803 Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II,” taking place on December 7, 2025, from 6:00 PM to 8:00 PM in room OCCC – West Halls B3–B4.
Dr. Jain’s presentation will highlight how machine learning models trained on real-world clinical data can identify patients who may benefit from earlier diagnostic workups for PNH—often before the disease has been formally recognized. This approach holds promise for shortening diagnostic delays, which are common in rare diseases and often lead to worse patient outcomes.
By demonstrating practical, real-world applications of AI in hematology, Atropos Health continues to position itself at the forefront of clinical innovation, blending data science with frontline patient care.
Integration of ASCO Guidelines Enhances Oncology Decision-Making
In parallel with the release of new AI algorithms, Atropos Health also announced the integration of ASCO’s widely respected clinical practice guidelines directly into its oncology platform. ASCO guidelines serve as the gold standard for evidence-based cancer treatment and care recommendations, guiding oncologists across a broad spectrum of cancer types, disease stages, and therapy options.
With this integration, physicians and researchers using the Atropos platform can now access the most current ASCO guidelines seamlessly within their clinical workflows. This enables faster, more informed decision-making and ensures that personalized patient care is aligned with the latest, peer-reviewed evidence.
By combining real-world evidence with established clinical guidelines, Atropos Health is creating a unified ecosystem where data-driven insights and expert consensus coexist. This integration supports oncologists in navigating increasingly complex treatment pathways, particularly as cancer care becomes more personalized and targeted based on molecular profiling, patient-specific risk factors, and real-world treatment responses.
The ASCO integration also underscores Atropos Health’s commitment to trust, transparency, and clinical rigor—values that are essential to the adoption of AI in healthcare.
Leadership Perspective on the Future of Oncology and Evidence-Based Medicine
Commenting on the significance of these announcements, Dr. Brigham Hyde, CEO and co-founder of Atropos Health, emphasized the transformative potential of combining AI with clinical guidelines.
The future of evidence-based medicine in oncology is being transformed by data and technology,” said Dr. Hyde. “With these two announcements—the integration of gold-standard ASCO Guidelines alongside the publication of additional AI models—we are advancing the next generation of precision medicine. By democratizing access to these models through public publication and enabling clinicians to access oncology guidelines directly within our platform, we are empowering care teams to navigate complex patient journeys with unprecedented clarity and deliver truly personalized, evidence-driven care.
Dr. Hyde’s statement reflects a broader industry shift toward embedding AI and real-world evidence more deeply into daily medical practice, moving beyond traditional research environments and into real-time clinical decision support.
Atropos Evidence™ Agent and EHR Integration Expand Point-of-Care Intelligence
Today’s announcement also builds on Atropos Health’s recent launch of the Atropos Evidence™ Agent, an advanced AI-powered expert agent designed to generate personalized real-world evidence. This agent represents a significant step forward in making actionable evidence available directly at the point of care.
Through collaboration with Stanford Health Care, Atropos Health is now embedding personalized real-world evidence within the electronic health record (EHR) using data from ChatEHR. This integration allows clinicians to access patient-specific insights during routine clinical encounters, enabling more informed and timely treatment decisions.
In addition, as part of a pilot collaboration with Microsoft, Atropos Health plans to combine ambient clinical encounter data from Dragon Copilot with the Atropos Evidence™ Agent. This integration aims to enhance the contextual understanding of patient interactions and automate the generation of real-world evidence based on conversational data captured during clinical visits.
Together, these developments illustrate Atropos Health’s broader strategy: to reduce the cognitive and administrative burden on clinicians while simultaneously elevating the quality, precision, and personalization of patient care.
Transforming the Oncology and Rare Disease Landscape with Real-World Evidence
The combined introduction of advanced AI for rare disease monitoring, the integration of ASCO clinical guidelines, and the expansion of the Atropos Evidence™ ecosystem represents a comprehensive evolution of the Atropos Health platform. These enhancements address several of the most pressing challenges in modern healthcare: delayed diagnosis in rare diseases, fragmented access to clinical guidelines, and limited real-time application of real-world evidence.
For oncology in particular, where treatment pathways are increasingly complex and individualized, the ability to synthesize real-world data, peer-reviewed guidelines, and AI-driven predictions within a single platform offers tremendous value. Clinicians can make more confident decisions, researchers can accelerate discovery, and patients can benefit from care that is both scientifically grounded and deeply personalized.
Atropos Health’s approach reflects a growing recognition that the future of healthcare lies at the intersection of data science, clinical expertise, and technology integration. By building tools that not only analyze data but also translate it into actionable insights, the company is helping to bridge the long-standing gap between research and real-world clinical practice.
As AI continues to reshape the way healthcare is delivered, Atropos Health’s latest advancements reaffirm its role as a pioneer in personalized evidence generation and precision medicine. With its expanding footprint in oncology, rare disease management, and real-world evidence integration, the company is poised to play an increasingly influential role in the next era of data-driven healthcare.
Looking ahead, Atropos Health’s continued collaboration with health systems, technology partners, and clinical organizations is expected to further extend the reach and impact of its platform—bringing cutting-edge AI and evidence-based tools to the forefront of everyday patient care.
About Atropos Health
Atropos Health is the developer of GENEVA OS®, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improve individual patient outcomes with data-driven care, expedite research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant, real-world evidence.
source link : https://www.businesswire.com
